Results 21 to 30 of about 198,762 (311)

Cancer vaccines [PDF]

OncoImmunology, 2013
These are exciting times for the field of cancer immunotherapy. Although the clinical efficacy of monoclonal antibodies has been demonstrated since the early 1990s, the therapeutic profile of other immunotherapeutic approaches-especially vaccines-has not yet been formally clarified.
Yaddanapudi, Kavitha, Mitchell, Robert A., Eaton, John W.   +2 more
openaire   +2 more sources

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland [PDF]

, 2014
In Scotland, a national HPV immunisation programme began in 2008 for 12-13 year olds, with a catch-up campaign from 2008-2011 for those under the age of 18.
Kavanagh, K, Cruickshank, M, Cubie, H., C Robertson, Pollock, Kevin G.J., J Love, Pollock, K G J, Potts, A., Love, J., K Kavanagh, Cruickshank, M., Nicoll, Sheila, Donaghy, Martin, Palmer, Tim J, K Cuschieri, Robertson, C, Palmer, T J, M Donaghy, Cuschieri, K., Robertson, C., H, Cubie,, Potts, Alison, H Cubie, M Cruickshank, Nicoll, S., Donaghy, M, Pollock, K. G. J., Potts, A, Love, John, Cuschieri, Kate, Kavanagh, K., Donaghy, M., S Nicoll, Cuschieri, K, Cubie, H, Nicoll, S, Cruickshank, Maggie, T J Palmer, Love, J, Kavanagh, Kimberley, K G J Pollock, Robertson, Chris, Palmer, T. J., A Potts   +43 more
core   +1 more source

Lung Cancer Vaccines [PDF]

The Cancer Journal, 2011
To date, in lung cancer, early attempts to modulate the immune system via vaccine-based therapeutics have been unsuccessful. An improved understanding of tumor immunology has facilitated the production of more sophisticated lung cancer vaccines. It is anticipated that it will likely require multiple epitopes of a diverse set of genes restricted to ...
Ronan J, Kelly, Giuseppe, Giaccone
openaire   +2 more sources

The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant [PDF]

, 2013
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials.
Cevayir Coban, Kenji Mizuguchi, Junichi Ito, Etsushi Kuroda, Coban, C, Ishii, KJ, Choon Kit Tang, Shizuo Akira, Jounai, N, Benoit H Dessailly, Ito, J, Keiichi Ohata, Tang, CK, Akira, S, Mizuguchi, K, Ken J Ishii, Kouji Kobiyama, Ohata, K, Nao Jounai, Kuroda, E, Kobiyama, K, Dessailly, BH, Aoshi, T, Taiki Aoshi   +23 more
core   +1 more source

Anti-cancer activity of plant-produced HPV16 E7 vaccine

, 2022
S.3018-3021The E7 oncoprotein from Human Papilloma Virus (HPV) is an attractive candidate for anti-cancer vaccine development. In this study, we engineered HPV16 E7 coding sequence (wild type or mutagenized sequence, E7GGG) as fusions to -1,3-1,4 ...
Massa, S., Muller, A., Venuti, A., Brandi, R., Mett, V., Franconi, R., Yusibov, V.   +6 more
core   +1 more source

Aging and Cancer Vaccines [PDF]

Critical Reviews in Oncogenesis, 2013
Cancer vaccination is less effective at old than at young age, due to T cell unresponsiveness. This is caused by age-related changes of the immune system. Major immune defects at older age are lack of naive T cells, impaired activation pathways of T cells and antigen-presenting cells (APC), and age-related changes in the tumor microenvironment (TME ...
Claudia, Gravekamp, Dinesh, Chandra
openaire   +2 more sources

Cancer vaccines and immunotherapy [PDF]

British Medical Bulletin, 2002
It is now clear that many human tumour antigens can be recognised by the immune system. These tumour antigens can be classified into several groups including cancer-testis, differentiation, tissue specific, over-expressed, and viral-associated antigens. In many cases, there is a known molecular basis of carcinogenesis which provides the explanation for
Said, Dermime, Anne, Armstrong, Robert E, Hawkins, Peter L, Stern   +3 more
openaire   +2 more sources

Cancer vaccines in the clinic

Bioengineering & Translational Medicine, 2023
AbstractVaccines are an important tool in the rapidly evolving repertoire of immunotherapies in oncology. Although cancer vaccines have been investigated for over 30 years, very few have achieved meaningful clinical success. However, recent advances in areas such antigen identification, formulation development and manufacturing, combination therapy ...
Morgan E. Janes, Alexander P. Gottlieb, Kyung Soo Park, Zongmin Zhao, Samir Mitragotri   +4 more
openaire   +3 more sources

Persistent serum protein signatures define an inflammatory subcategory of long COVID

Nature Communications, 2023
Long COVID or post-acute sequelae of SARS-CoV-2 (PASC) is a clinical syndrome featuring diverse symptoms that can persist for months following acute SARS-CoV-2 infection.
Aarthi Talla, Suhas V. Vasaikar, Gregory Lee Szeto, Maria P. Lemos, Julie L. Czartoski, Hugh MacMillan, Zoe Moodie, Kristen W. Cohen, Lamar B. Fleming, Zachary Thomson, Lauren Okada, Lynne A. Becker, Ernest M. Coffey, Stephen C. De Rosa, Evan W. Newell, Peter J. Skene, Xiaojun Li, Thomas F. Bumol, M. Juliana McElrath, Troy R. Torgerson   +19 more
doaj   +1 more source

Cancer vaccines

BMJ, 2015
Cancer vaccines are designed to promote tumor specific immune responses, particularly cytotoxic CD8 positive T cells that are specific to tumor antigens. The earliest vaccines, which were developed in 1994-95, tested non-mutated, shared tumor associated antigens that had been shown to be immunogenic and capable of inducing clinical responses in a ...
openaire   +3 more sources